Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Valve Choice in patients with Chronic Kidney Disease
FY 2018-19
Summary
Heart disease is the most common cause of death in patients with chronic kidney disease (CKD). Affecting three million Canadians, CKD can progress to end-stage renal disease (ESRD) when patients require dialysis. Valvular heart disease is found in over 30% of patients with ESRD and diagnosed at a rate four to five times higher than the general population. As a result, a large proportion of patients with ESRD need valve replacement surgery to relieve symptoms and prevent permanent heart damage. Native valves can be replaced with a mechanical or bioprosthetic valve, each with their own advantages and disadvantages. Mechanical valves are more durable, but require life-long blood thinning medication (i.e. warfarin) to prevent clot formation on the valve and other parts of the body. In addition to challenges of medication adherence, blood thinning medication is associated with increased risk of bleeding. Bioprosthetic valves, made with tissue, avoid life-long blood thinning medication and its complications, but are less durable and require a complex reoperation long-term. Currently, there is a lack of research to support choosing either valve in patients with ESRD, contributing to variable clinical practice amongst physicians.
Using various types of studies, we will 1) Describe the quality of current research. 2) Describe the preferences of patients and physicians for different prosthetic valves. 3) Evaluate outcomes of patients with ESRD who previously received either valve, using advanced statistics. 4) Evaluate outcomes of valve surgery in patients in earlier stages of CKD.
These studies will evaluate the best valve given current body of scientific evidence, and contribute new evidence that improves on the shortcomings of past research. The evidence gained from these studies will inform a randomized control trial in this patient population. Ultimately, we hope to improve the decision making and outcomes of patients with CKD who require valve replacement surgery.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
404087
Name
Kim Kevin S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Valve Choice in patients with Chronic Kidney Disease
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Biostatistics; Chronic Kidney Disease; Clinical Epidemiology; Dialysis; End-Stage Renal Disease; Systematic Review And Meta Analysis; Valve Heart Disease
Abstract
Heart disease is the most common cause of death in patients with chronic kidney disease (CKD). Affecting three million Canadians, CKD can progress to end-stage renal disease (ESRD) when patients require dialysis. Valvular heart disease is found in over 30% of patients with ESRD and diagnosed at a rate four to five times higher than the general population. As a result, a large proportion of patients with ESRD need valve replacement surgery to relieve symptoms and prevent permanent heart damage. Native valves can be replaced with a mechanical or bioprosthetic valve, each with their own advantages and disadvantages. Mechanical valves are more durable, but require life-long blood thinning medication (i.e. warfarin) to prevent clot formation on the valve and other parts of the body. In addition to challenges of medication adherence, blood thinning medication is associated with increased risk of bleeding. Bioprosthetic valves, made with tissue, avoid life-long blood thinning medication and its complications, but are less durable and require a complex reoperation long-term. Currently, there is a lack of research to support choosing either valve in patients with ESRD, contributing to variable clinical practice amongst physicians.
Using various types of studies, we will 1) Describe the quality of current research. 2) Describe the preferences of patients and physicians for different prosthetic valves. 3) Evaluate outcomes of patients with ESRD who previously received either valve, using advanced statistics. 4) Evaluate outcomes of valve surgery in patients in earlier stages of CKD.
These studies will evaluate the best valve given current body of scientific evidence, and contribute new evidence that improves on the shortcomings of past research. The evidence gained from these studies will inform a randomized control trial in this patient population. Ultimately, we hope to improve the decision making and outcomes of patients with CKD who require valve replacement surgery.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kim, Kevin S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~